Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Early-onset colorectal cancer behaves differently — and that matters. A large Australian study found that patients under 50 with liver-only metastases had distinct tumor biology, fewer comorbidities, and significantly longer survival than older patients. Researchers say personalized treatment — not a blanket approach — is key.
A retrospective study of nearly 1,700 Australians found that early-onset colorectal cancer (diagnosed before age 50) with liver-only metastases is biologically distinct from late-onset disease — and those differences have real treatment implications. Younger patients were more likely to be women, have left-sided or rectal tumors, and present with synchronous metastases. They also had better functional status and fewer comorbidities, and were offered active treatment at higher rates.
Survival outcomes also diverged sharply. Patients with early-onset disease had a median overall survival of 3.2 years vs. 2.38 years for late-onset — and among those with metachronous metastases, the gap widened dramatically (8.86 vs. 3.83 years). Notably, survival was nearly identical between age groups among those who underwent liver resection.
Key Takeaways:
Why it matters: With early-onset colorectal cancer rising globally, understanding its unique biology is critical. This study reinforces the need for individualized, multidisciplinary treatment planning — and flags NRAS mutations as a novel prognostic factor worth further investigation.
